Top-Rated Dividend StocksTop-Rated DividendPositive News SentimentPositive NewsNASDAQ:RPRX Royalty Pharma (RPRX) Stock Price, News & Analysis → Jeff Bezos & 48 Members of Congress Are Buying ONE Sector… (From InvestorPlace) (Ad) Free RPRX Stock Alerts $26.92 -0.28 (-1.03%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$26.71▼$27.2050-Day Range$26.39▼$29.7252-Week Range$25.92▼$32.36Volume1.91 million shsAverage Volume2.62 million shsMarket Capitalization$16.08 billionP/E Ratio20.09Dividend Yield3.12%Price Target$43.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Royalty Pharma alerts: Email Address Royalty Pharma MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside59.7% Upside$43.00 Price TargetShort InterestHealthy3.45% of Float Sold ShortDividend StrengthModerateBased on Four FactorsSustainability-2.25Upright™ Environmental ScoreNews Sentiment1.58Based on 7 Articles This WeekInsider TradingN/AProj. Earnings Growth9.18%From $4.03 to $4.40 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.89 out of 5 starsFinance Sector52nd out of 878 stocksPharmaceutical Preparations Industry8th out of 429 stocks 3.4 Analyst's Opinion Consensus RatingRoyalty Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRoyalty Pharma has only been the subject of 2 research reports in the past 90 days.Read more about Royalty Pharma's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.45% of the float of Royalty Pharma has been sold short.Short Interest Ratio / Days to CoverRoyalty Pharma has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Royalty Pharma has recently decreased by 0.23%, indicating that investor sentiment is improving. Previous Next 2.5 Dividend Strength Dividend YieldRoyalty Pharma pays a meaningful dividend of 3.12%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthRoyalty Pharma does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Royalty Pharma is 62.69%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Royalty Pharma will have a dividend payout ratio of 19.09% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend.Read more about Royalty Pharma's dividend. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRoyalty Pharma has received a 47.64% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Rotavirus vaccine", "HIV medication", "Breast cancer medication", "Prostate cancer medication", "Rheumatoid arthritis medication", and "Multiple myeloma medication" products. See details.Environmental SustainabilityThe Environmental Impact score for Royalty Pharma is -2.25. Previous Next 4.2 News and Social Media Coverage News SentimentRoyalty Pharma has a news sentiment score of 1.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Finance companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Royalty Pharma this week, compared to 4 articles on an average week.Search Interest14 people have searched for RPRX on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat Follows12 people have added Royalty Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Royalty Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders18.90% of the stock of Royalty Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.35% of the stock of Royalty Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Royalty Pharma's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Royalty Pharma are expected to grow by 9.18% in the coming year, from $4.03 to $4.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Royalty Pharma is 20.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.21.Price to Earnings Ratio vs. SectorThe P/E ratio of Royalty Pharma is 20.09, which means that it is trading at a less expensive P/E ratio than the Finance sector average P/E ratio of about 38.70.Price to Earnings Growth RatioRoyalty Pharma has a PEG Ratio of 3.51. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRoyalty Pharma has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Royalty Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market…Click here for the details About Royalty Pharma Stock (NASDAQ:RPRX)Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.Read More RPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RPRX Stock News HeadlinesJune 12, 2024 | benzinga.comWall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend YieldsJune 5, 2024 | investorplace.comJune's Biotech Boom: 3 Stocks to Buy for a Summertime SurgeJune 4, 2024 | globenewswire.comRoyalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceJune 3, 2024 | globenewswire.comRoyalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured NotesMay 29, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Merus (MRUS), Royalty Pharma (RPRX)May 28, 2024 | msn.comWhy Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?May 28, 2024 | globenewswire.comRoyalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 MillionMay 23, 2024 | markets.businessinsider.comHeart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts ObserveMay 22, 2024 | marketwatch.comCytokinetics Falls 10% on Royalty Pharma Transaction, Stock OfferMay 22, 2024 | msn.comCytokinetics to get up to $575M in funding from Royalty PharmaMay 22, 2024 | globenewswire.comRoyalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D PipelineMay 20, 2024 | investorplace.com7 Dividend Stocks to Buy at a 52-Week LowMay 13, 2024 | finance.yahoo.comRoyalty Pharma to Present at Upcoming Investor ConferencesMay 12, 2024 | finance.yahoo.comHere's What Analysts Are Forecasting For Royalty Pharma plc (NASDAQ:RPRX) After Its First-Quarter ResultsMay 11, 2024 | finance.yahoo.comOnly Four Days Left To Cash In On Royalty Pharma's (NASDAQ:RPRX) DividendMay 11, 2024 | seekingalpha.comRoyalty Pharma: Solid Start Of The Year, Buy ConfirmedMay 10, 2024 | msn.comRoyalty Pharma plc (NASDAQ:RPRX) Q1 2024 Earnings Call TranscriptMay 10, 2024 | uk.finance.yahoo.comQ1 2024 Royalty Pharma PLC Earnings CallMay 9, 2024 | finanznachrichten.deRoyalty Pharma plc: Royalty Pharma to Acquire Royalty Interest in Sanofi's FrexalimabMay 9, 2024 | markets.businessinsider.comRoyalty Pharma Beats Q1 Earnings and Revenue EstimatesMay 9, 2024 | investorplace.comRPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | globenewswire.comRoyalty Pharma to Acquire Royalty Interest in Sanofi's FrexalimabMay 4, 2024 | finance.yahoo.comRoyalty Pharma's (NASDAQ:RPRX) Dividend Will Be $0.21April 20, 2024 | finance.yahoo.comRoyalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21April 19, 2024 | globenewswire.comRoyalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024See More Headlines Receive RPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Ex-Dividend for 6/14 Dividend5/16/2024Dividend Payable6/14/2024Today6/16/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorFinance Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RPRX CUSIP76028H20 CIK897075 Webwww.royaltypharma.com Phone212-883-0200FaxN/AEmployees51Year Founded1996Price Target and Rating Average Stock Price Target$43.00 High Stock Price Target$57.00 Low Stock Price Target$28.00 Potential Upside/Downside+59.7%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$1.34 Trailing P/E Ratio20.09 Forward P/E Ratio6.68 P/E Growth3.55Net Income$1.13 billion Net Margins35.70% Pretax Margin53.03% Return on Equity22.94% Return on Assets13.78% Debt Debt-to-Equity Ratio0.62 Current Ratio12.52 Quick Ratio12.52 Sales & Book Value Annual Sales$2.36 billion Price / Sales6.83 Cash Flow$4.52 per share Price / Cash Flow5.96 Book Value$16.88 per share Price / Book1.59Miscellaneous Outstanding Shares597,440,000Free Float484,521,000Market Cap$16.08 billion OptionableOptionable Beta0.47 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Pablo Gerardo Legorreta (Age 59)Founder, Chairman of the Board & CEO Mr. Terrance P. CoyneExecutive VP & CFOMr. George Wingate Lloyd (Age 64)Executive VP of Investments & Chief Legal Officer Comp: $4.56MMr. Christopher Hite (Age 56)Vice Chairman & Executive VP Comp: $4.56MDr. Marshall Jonathan Urist M.D. (Age 48)Ph.D., Executive Vice President of Research & Investments Comp: $4.56MMr. Arthur Richard McGivern J.D.Executive Vice President of Investments & General CounselMr. Ashwin Pai M.D.Executive Vice President of InvestmentsMs. Kristin Stafford (Age 42)Senior VP & Chief Accounting Officer Mr. Eric Cornelius SchneiderSenior VP & Chief Technology OfficerDr. James Folmar Reddoch Ph.D. (Age 54)Executive VP of Investments & Chief Scientific Officer Comp: $3.4MMore ExecutivesKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZHorizon Therapeutics PublicNASDAQ:HZNPPerrigoNYSE:PRGOCorcept TherapeuticsNASDAQ:CORTSupernus PharmaceuticalsNASDAQ:SUPNView All CompetitorsInsiders & InstitutionsDekaBank Deutsche GirozentraleBought 276,546 shares on 6/4/2024Ownership: 0.125%Aurora Investment CounselBought 2,827 shares on 6/4/2024Ownership: 0.007%Swedbank ABBought 8,279,900 shares on 5/21/2024Ownership: 1.386%Atria Investments IncBought 39,019 shares on 5/21/2024Ownership: 0.007%iA Global Asset Management Inc.Sold 3,981 shares on 5/17/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions Should I Buy Royalty Pharma Stock? RPRX Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Royalty Pharma plc: Royalty Pharma plc has a diverse portfolio of royalties on approximately 35 commercial products and 14 development-stage product candidates covering various therapeutic areas, providing potential for revenue growth and stability. The company collaborates with a wide range of innovators from academic institutions, research hospitals, biotechnology companies, and pharmaceutical companies, enhancing its access to cutting-edge biopharmaceutical innovations. Royalty Pharma plc has a solid financial performance, with a strong net margin of 35.70% and a return on equity of 22.94%, indicating efficient operations and profitability. The company's stock price has shown resilience, with a 52-week low of $25.92 and a 52-week high of $34.65, demonstrating potential for capital appreciation and stability in share value. Royalty Pharma plc offers a quarterly dividend, with a dividend yield of 3.06%, providing investors with a potential income stream alongside capital gains. Cons Investors should be bearish about investing in Royalty Pharma plc for these reasons: The company's stock price has experienced fluctuations, with a current market price of $27.48, potentially indicating volatility and uncertainty in share value. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, June 8, 2024. Please send any questions or comments about these Royalty Pharma pros and cons to contact@marketbeat.com. RPRX Stock Analysis - Frequently Asked Questions Should I buy or sell Royalty Pharma stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RPRX shares. View RPRX analyst ratings or view top-rated stocks. What is Royalty Pharma's stock price target for 2024? 5 equities research analysts have issued 1 year price objectives for Royalty Pharma's stock. Their RPRX share price targets range from $28.00 to $57.00. On average, they expect the company's stock price to reach $43.00 in the next twelve months. This suggests a possible upside of 59.7% from the stock's current price. View analysts price targets for RPRX or view top-rated stocks among Wall Street analysts. How have RPRX shares performed in 2024? Royalty Pharma's stock was trading at $28.09 at the beginning of 2024. Since then, RPRX shares have decreased by 4.2% and is now trading at $26.92. View the best growth stocks for 2024 here. When is Royalty Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our RPRX earnings forecast. How were Royalty Pharma's earnings last quarter? Royalty Pharma plc (NASDAQ:RPRX) announced its earnings results on Thursday, May, 9th. The biopharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.02. The biopharmaceutical company earned $568 million during the quarter, compared to the consensus estimate of $671.45 million. Royalty Pharma had a trailing twelve-month return on equity of 22.94% and a net margin of 35.70%. During the same quarter in the prior year, the firm posted $1.60 EPS. How often does Royalty Pharma pay dividends? What is the dividend yield for Royalty Pharma? Royalty Pharma announced a quarterly dividend on Wednesday, April 17th. Stockholders of record on Friday, May 17th will be given a dividend of $0.21 per share on Friday, June 14th. This represents a $0.84 dividend on an annualized basis and a yield of 3.12%. The ex-dividend date is Thursday, May 16th. Read our dividend analysis for RPRX. Is Royalty Pharma a good dividend stock? Royalty Pharma (NASDAQ:RPRX) pays an annual dividend of $0.84 per share and currently has a dividend yield of 3.12%. The dividend payout ratio is 62.69%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RPRX will have a dividend payout ratio of 19.09% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for RPRX. What ETFs hold Royalty Pharma's stock? ETFs with the largest weight of Royalty Pharma (NASDAQ:RPRX) stock in their portfolio include Tema Global Royalties ETF (ROYA), iShares U.S. Pharmaceuticals ETF (IHE), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Formidable ETF (FORH), Fidelity Disruptive Medicine ETF (FMED), First Trust Health Care AlphaDEX Fund (FXH) and Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of Royalty Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Royalty Pharma investors own include Twitter (TWTR), Bausch Health Companies (BHC), NVIDIA (NVDA), (RLYP) (RLYP), Aeterna Zentaris (AEZS), Advanced Micro Devices (AMD), Netflix (NFLX), QUALCOMM (QCOM), Salesforce (CRM) and Twilio (TWLO). When did Royalty Pharma IPO? Royalty Pharma (RPRX) raised $1.9 billion in an initial public offering (IPO) on Tuesday, June 16th 2020. The company issued 70,000,000 shares at a price of $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank served as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers. Who are Royalty Pharma's major shareholders? Royalty Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.31%), Baillie Gifford & Co. (2.79%), Swedbank AB (1.39%), Homestead Advisers Corp (0.32%), Mitsubishi UFJ Trust & Banking Corp (0.31%) and Janus Henderson Group PLC (0.31%). Insiders that own company stock include 1978 Sicaf Sif SA - Gg St Gg, 1978 Sicaf Sif SA Gg, Avara Management Ltd, George W Lloyd, Henry A Fernandez, James F Reddoch, James F Reddoch, Mario Germano Giuliani, Marshall Urist, Pablo G Legorreta, Rory B Riggs, Scientific Corp Boston and Terrance P Coyne. View institutional ownership trends. How do I buy shares of Royalty Pharma? Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RPRX) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Royalty Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Royalty Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
